Did Revolution Medicines threaten to sue Erasca?
Yes, Regencell Bioscience Holdings Limited (RGC) completed a 38-for-one forward stock split in June 2025. The company announced this split on June 2, 2025, and established a record date of June 12, 2025. Following this action, shareholders received 37 additional shares for every one share they previously held. Trading for the company's common stock on a post-split adjusted basis officially commenced on June 16, 2025. This corporate action was implemented to adjust the company's capital structure, and shareholders were advised to review their brokerage accounts to see the updated share counts resulting from the distribution of these additional shares.
Related FAQs
Erasca (ERAS) is currently classified by many financial analysts as a "Buy," reflecting professional optimism regarding its potential in the precision oncology market.
The consensus among Wall Street analysts covering Erasca (ERAS) is currently a "Buy.